Pacira BioSciences

Key points from this report:

 

  • Buy Pacira Biosciences (PCRX). The stock is actionable after breaking out of a 13-week consolidation base on above average volume. Buy at current levels or on any constructive pullback to the rising 10-DMA.
  • Strong post COVID-19 recovery. Exparel net product sales for October came in at $40.7M (+112% y/y). The drug has outpaced the elective surgery market throughout the pandemic. According to weekly data from mid-October, elective surgery procedures in the U.S. were down 26% while Exparel sales were up 13%. Management believes 90%+ of delayed procedures will be performed this year, with 2021 a substantial improvement over 2020.
  • No competition until mid-2021. The U.S. FDA has classified Heron Therapeutics’ (HRTX) application for HTX-011 as class-2 submission, which indicates the agency could take up to six months to review the new information.
  • Looking forward. The company will announce Q4 results in February. For 2020, consensus expects revenue and EPS growth of 2% and 26%, y/y, respectively. Consensus expects 2021 revenue and EPS growth of 26% and 74%, y/y, respectively
  • See other ideas in our O’Neil Health Care Weekly

Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq are trading near all-time highs,

holding above 21-DMA support (S&P 500: 3,466; Nasdaq: 11,532) after reversing off intraday highs on Mon-
day. The distribution day count stands at seven and six, respectively, with one expiring on the S&P 500 Monday

and another on Tuesday.

Market View

U.S. Market
The U.S. market is in a Confirmed Uptrend. The S&P 500 and Nasdaq regained their respective 50-DMA this
week and are now testing resistance at October highs (S&P 500: 3,550; Nasdaq: 11,965). The 10- and 21-

DMA have begun to turn back up and will now act as near-term resistance should a pullback occur. The distri-
bution day count stands at seven and five, respectively, with one day expiring on each Monday.

Market View

U.S. Market
The U.S. market is in an Uptrend Under Pressure. The S&P 500 and Nasdaq broke below their respective 50-
DMA this week and are now testing support near September lows, followed by the rising 200-DMA (S&P 500:
3,129; Nasdaq: 9,833). We will likely downgrade the market to Downtrend for the first time since the April
2 follow-through day should either index close below September lows (S&P 500: 3,209; Nasdaq: 10,519).
Should that occur, we will be looking for another follow-through day before advising an increase in risk.

Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq held above their respective 50-
DMA (S&P 500: 3,408; Nasdaq: 11,305) following a low volume pullback to that level this week. That moving
average remains near-term support, while resistance remains 3,550 on the S&P 500 and 11,965 on the
Nasdaq. The distribution day count stands at six and three, respectively, with one day expiring on each next
week.